Targeted Oncology· @TargetedOnc · X·· 23 小时前评分70
正文 · 原文
KEYNOTE-B49 at #ESMO26 raises a fundamental question:
PFS improved (HR 0.74), but median PFS was 6.7 vs 6.0 months, with no OS benefit (HR 1.04).
Are we looking at a statistically positive trial or a clinically meaningful advance?
#BreastCancer
63 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com